An irreversible ErB-family blocker, afatinib, retains its inhibitory effects on signal transduction and in vitro and in vivo cancer cell growth in tumors resistant to reversible EGFR inhibitors, such as those harboring the T790M mutation [13]. Here, EGFR is linked to cancer.